Chemomab Q2 Update

 ──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)──

──Establishes Clinical Proof-of-Concept for Disease-Modifying Potential of CM-101 and Provides Foundation for Advancing to PSC Phase 3 Pivotal Trial──

──Completed PIPE Financing Including Major New and Existing Investors that Extends Cash Runway Through Beginning of 2026──

──On Track to Achieve Key Clinical Milestones in First Quarter of 2025; Continuing Discussions with Potential Partners──

https://www.globenewswire.com/news-release/2024/08/21/2933381/0/en/Chemomab-Therapeutics-Announces-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html